Tessara Therapeutics

Name

Tessara Therapeutics

Legal name

Tessara Therapeutics Pty Ltd

Website

https://tessaratherapeutics.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Preclinical CNS Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

Keywords

• 3D neural tissue models
• CNS drug discovery services
• Alzheimer's disease models
• IPSC-derived micro-tissues
• Preclinical neural screening

Headquarters

HQ city

Not specified

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. RealBrain® Screening Services: Provides end-to-end 3D neural screening services on validated models (ArtiBrain™ and ADBrain™) including safety & cytotoxicity profiling, neuroinflammation assessment, target validation, neurodegeneration analysis, and neural network mapping. Services delivered as contracted research studies.
2. Custom Model Development: Bespoke 3D models and assays designed around customer therapeutic targets and mechanisms. Tailored assay panels and dosing regimens for unique compound classes or mechanisms of action.
3. Custom Assay Development: Design of study protocols and assay panels to fit unique customer requirements for neural tissue analysis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Tessara Therapeutics provides human-relevant 3D neural micro-tissue models built on its proprietary RealBrain® synthetic hydrogel platform. It sells and screens two main model products — ArtiBrain™ (healthy human brain baseline) and ADBrain™ (Alzheimer's disease pathology) — and delivers end-to-end contracted screening, custom assay development, and custom model development services for CNS drug discovery customers in pharma, biotech, and academia.

Product overview

Tessara Therapeutics operates as a platform company centered on its proprietary RealBrain® technology, which provides validated 3D neural micro-tissue models for preclinical neuroscience drug discovery. The core platform encompasses two distinct product models: ArtiBrain™ (healthy human brain baseline) and ADBrain™ (Alzheimer's disease pathology model). Both models are offered as integrated service offerings that include assay screening across safety/cytotoxicity, neuroinflammation, target validation, neurodegeneration, and neural network analysis. Custom model development is available for bespoke therapeutic targets.

Differentiator

Problem solved

Functional benefit

Brands

• RealBrain®: Proprietary 3D neural micro-tissue technology platform using human iPSC-derived neural stem cells to create brain-like extracellular matrix for drug discovery applications
• ArtiBrain™
• ADBrain™

Products and services

• ArtiBrain™ Healthy Human Brain Model Healthy human brain 3D micro-tissue model derived from human iPSCs; provides a physiologically relevant baseline for compound safety, network analysis, and early discovery research, with single tissue per well in standard 96- and 384-well formats. Intended for pharmaceutical, biotech, and academic researchers in CNS drug discovery.
• ADBrain™ Alzheimer's Disease Model Alzheimer's disease 3D micro-tissue model that replicates hallmark features of sporadic Alzheimer's disease including amyloid accumulation (Aβ42), tau phosphorylation (pTau181, 217, 231), disrupted networks, and neuroinflammation in approximately three weeks. Intended for Alzheimer's disease therapeutic screening and disease modeling researchers.
• RealBrain® Screening Services End-to-end 3D neural screening services on validated RealBrain® models including safety & cytotoxicity profiling, neuroinflammation assessment, target validation, neurodegeneration analysis, and neural network mapping. Delivered as contracted research studies to pharma, biotech, and academic customers.
• Custom Model and Assay Development Bespoke 3D model and assay design service that builds tailored models and assay panels around customer therapeutic targets and mechanisms, with custom dosing regimens for unique compound classes or mechanisms of action. Delivered as contracted projects to pharma and biotech discovery teams.

Quantifiable outcome

• 50% reduction in Aβ42 and 26% increase in neuronal viability demonstrated in client studies
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

One partnership is on record.

• InSphero Inc.minorOthersDr Jan Lichtenberg, CEO of Swiss- and US-based InSphero Inc. (largest biotech specialized in 3D cell-culture technologies for discovery and safety), serves on Tessara's advisory board. InSphero specializes in 3D cell culture technologies. This represents a personal advisory connection rather than a formal corporate partnership.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• InSphero: Swiss/US-based leader in 3D cell-culture technologies for drug discovery and safety. Directly comparable to Tessara as both offer proprietary 3D in vitro models delivered as services to pharma/biotech. InSphero's CEO sits on Tessara's advisory board, underscoring the close technology and customer overlap.
• NeuCyte: US-based company developing iPSC-derived neural cell models and 3D neural cultures for CNS drug discovery. Directly comparable product/market overlap with Tessara's RealBrain® platform and Alzheimer's-focused screening offering.
• Axol Bioscience: UK-based supplier of iPSC-derived neural cells and 3D neuroscience models for academic and pharma research. Overlaps with Tessara in iPSC-derived human neural models for CNS drug discovery, though Axol sells more as a catalog reagent supplier.

Others

• Corning Life Sciences: Major supplier of cell-culture plastics, Matrigel ECM matrix, and 3D culture vessels widely used as enabling infrastructure for organoid and 3D neural workflows. Relevant ecosystem peer to Tessara as a foundational supplier rather than a direct competitor.

Broad incumbents

• Thermo Fisher Scientific: Global life-sciences tools major with extensive cell culture, 3D model, and drug-discovery services portfolios. Relevant incumbent comparable to Tessara via its Gibco cell-culture reagents, 3D culture systems, and PPD preclinical services.
• Charles River Laboratories: Large preclinical CRO offering broad safety assessment, in vitro services, and neuroscience research models. Comparable to Tessara in pharma-facing CNS preclinical services, but with vastly greater scale, model breadth, and global footprint.
• Molecular Devices: Established life-science instrumentation provider of high-content imaging and screening platforms widely used in pharma drug discovery workflows. Comparable to Tessara's screening infrastructure (high-content confocal imaging and automated image analysis), but as a broad tools incumbent rather than a neural-model specialist.

Emerging players

• Emulate: US-based organ-on-chip company offering microphysiological systems and biological models for drug discovery. Partial overlap with Tessara via human-relevant in vitro models for preclinical testing, with a distinct chip-based delivery mechanism.
• CN Bio: UK-based organ-on-chip company providing microphysiological systems and in vitro models for drug discovery and safety assessment. Adjacent competitor to Tessara in the human-relevant preclinical model space, differentiated by chip-based architecture.
• BrainXell: US-based supplier of iPSC-derived neural cell products and 3D neural cultures for neuroscience research and drug discovery. Comparable customer base and product category to Tessara, though more catalog-style reagent offering.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/tessara-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tessara Therapeutics